Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Algorithm to identify responders to short-term esomeprazole (Nexium) in primary care
2006-000574-69Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esomeprazole in Acid Peptic Disease (APD), gastroesophageal reflux disease (GERD) and dyspepsia, sponsored by AstraZeneca. Primary endpoint: Response rate to empirical esomeprazole treatment. Started Mar 2006; status: completed.
02
Drugs
esomeprazole
03
Conditions
Acid Peptic Disease (APD)gastroesophageal reflux disease (GERD)dyspepsia
Beyond the preview
Go deeper on 2006-000574-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000574-69.